足月引产:阴道米索前列醇与地诺前列酮栓的非劣效随机对照试验
这项多中心开放标签非劣效随机试验纳入1674例≥36周、Bishop评分≤5的单胎头位无剖宫产史孕妇,比较每4小时25μg阴道米索前列醇与10mg缓释地诺前列酮栓引产。主要结局剖宫产率两组分别为22.1%和19.9%,差异2.2%(95%CI上限5.6%),未能证明非劣效(P=.092);但米索组24小时内阴道分娩率更高且产妇满意度更好,新生儿和产妇发病率相似。
要点
- 米索前列醇25μg每4小时与地诺前列酮栓10mg引产的剖宫产率差异未达非劣效界值。
- 米索组24小时内阴道分娩率显著更高(59.3% vs 45.7%)。
- 两组新生儿和产妇发病率相似,临床风险获益比支持两者均可使用。
核心结论
- 未能证明每4小时25μg阴道米索前列醇在足月引产剖宫产率方面非劣效于地诺前列酮栓,但差异置信上限仅略超非劣效界值。
- 鉴于剖宫产率差异小且母婴发病率相似,两种药物的临床风险获益比均合理。
研究设计与样本
- 多中心、开放标签、随机、非劣效试验,2012至2015年在4所大学医院开展。
- 纳入1674例因医学原因引产、≥36周、Bishop评分≤5、单胎头位、无剖宫产史的孕妇。
- 随机分为阴道米索前列醇25μg每4小时组或10mg缓释地诺前列酮栓组。
- 主要结局为总剖宫产率,非劣效界值定义为组间差异不超过5%。
主要发现
- 符合方案分析每组790例,剖宫产率米索组22.1%(n=175) vs 地诺组19.9%(n=157),差异2.2%(95%CI上限5.6%),P=.092。
- 意向性分析结果相似。
- 两组新生儿和产妇发病率相似。
- 米索组24小时内阴道分娩率显著更高(59.3% vs 45.7%,P<.001)。
- 米索组产妇满意度视觉模拟评分更高(平均7.1±2.4 vs 5.8±3.1,P<.001)。
关键数值与推荐
- 非劣效界值:剖宫产率组间差异不超过5%。
- 主要结局差异2.2%,95%CI上限5.6%,超过非劣效界值。
- 米索组24小时内阴道分娩率59.3% vs 地诺组45.7%(P<.001)。
- 产妇满意度评分米索组7.1±2.4 vs 地诺组5.8±3.1(P<.001)。
临床怎么用
- 对于足月Bishop评分≤5的引产孕妇,米索前列醇25μg每4小时和地诺前列酮栓10mg均可选用。
- 米索前列醇可能提高24小时内阴道分娩率和产妇满意度,但需注意剖宫产率非劣效未证实。
- 决策时应结合母婴发病率相似的特点及患者偏好个体化选择。
局限性
- 开放标签设计可能影响主观结局(如满意度)的评估。
- 非劣效性未证实,置信上限仅略超界值,需谨慎解读。
- 原文未报告盲法、样本量计算细节及经济数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Induction of labor is among the most common procedures for pregnant women. Only a few randomized clinical trials with relatively small samples have compared misoprostol with dinoprostone. Although their efficacy seems similar, their safety profiles have not been adequately evaluated, and economic data are sparse. OBJECTIVE: This study aimed to test the noninferiority of vaginal misoprostol (prostaglandin E1) (25 μg) to a slow-release dinoprostone (prostaglandin E2) pessary (10 μg) for induction of labor with an unfavorable cervix at term. STUDY DESIGN: This was an open-label multicenter randomized noninferiority trial at 4 university hospitals of the Research Group in Obstetrics and Gynecology between 2012 and 2015. We recruited women who underwent induction of labor for medical reasons, those with a Bishop score of ≤5 at ≥36 weeks' gestation, and those with a cephalic-presenting singleton pregnancy with no previous cesarean delivery. Women were randomly allocated to receive either vaginal misoprostol at 4-hour intervals (25 μg) or a 10-mg slow-release dinoprostone pessary. The primary outcome was the total cesarean delivery rate. Noninferiority was defined as a difference in the cesarean delivery rates between the groups of no more than 5%. Secondary outcomes included neonatal and maternal morbidity, vaginal delivery at <24 hours after starting the induction of labor process, and maternal satisfaction. RESULTS: The study included 1674 randomized women. The per-protocol analysis included 790 women in each group. The total cesarean delivery rates were 22.1% (n=175) in the misoprostol group and 19.9% (n=157) in the dinoprostone group, a difference of 2.2% (with an upper-bound 95% confidence limit of 5.6%) (P=.092). Results in the intention-to-treat analysis were similar. Neonatal and maternal morbidity rates were similar between groups. Vaginal delivery within 24 hours was significantly higher in the misoprostol group (59.3% vs 45.7%; P<.001) as was maternal satisfaction, assessed in the postpartum period by a visual analog scale (mean score, 7.1±2.4 vs 5.8±3.1; P<.001). CONCLUSION: The noninferiority of a 25-μg dose of vaginal misoprostol every 4 hours to the dinoprostone pessary for cesarean delivery rates after induction of labor at term could not be demonstrated, although the confidence limit of the difference barely exceeded the noninferiority margin. Nonetheless, given the small difference between these cesarean delivery rates and the similarity of neonatal and maternal morbidity rates in this large study, the clinical risk-to-benefit ratio justifies the use of both drugs.
引用
- Gaudineau A, Senat MV, Ehlinger V, et al. Induction of labor at term with vaginal misoprostol or a prostaglandin E2 pessary: a noninferiority randomized controlled trial. Am J Obstet Gynecol. 2021. PMID: 33887241. doi:10.1016/j.ajog.2021.04.226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。